Promising phase II data on cabozantinib in patients with prostate cancer and soft tissue disease Feb. 22, 2011
Initial doses of TRC-105 are tolerated in patients with castration-resistant prostate cancer Feb. 22, 2011
Threshold Pharma and FDA agree on SPA for phase III TH-302 trial in soft tissue sarcoma Feb. 18, 2011
RSS